RESPILIQ - enteral CO2 absorption for the therapy of hypercapnic lung failure

Información del proyecto

RESPILIQ

Identificador del acuerdo de subvención: 101166201

DOI

10.3030/101166201

Proyecto cerrado

Fecha de la firma de la CE 6 Julio 2024

Fecha de inicio 1 Mayo 2024

Fecha de finalización 30 Abril 2026

Financiado con arreglo a

• The European Innovation Council (EIC)

Coste total

€ 3 603 638,83

Aportación de la UE

€ 2 499 999,00

Coordinado por

O11 BIOMEDICAL GMBH
Germany

Periodic Reporting for period 1 - RESPILIQ (RESPILIQ - enteral CO2 absorption for the therapy of hypercapnic lung failure)

Período documentado: 2024-05-01 hasta 2025-04-30

Resumen del contexto y de los objetivos generales del proyecto

Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of death worldwide, affecting millions of people with a high socioeconomic burden. The major challenge in the treatment of COPD patients is hypercapnia (too much CO2 in the blood). Standard treatment involves non-invasive ventilation (NIV) affecting the quality of life significantly. As a result, many patients with COPD continue to struggle with hypercapnia.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

RESPILIQ™ (the liquid breath) is a novel therapeutic approach (medical device) that uses the intestine as an alternative gas exchange organ to eliminate CO2. This allows the lung to rest and avoid further damage by intensive ventilation therapies. We have developed a pilot plant and in our preclinical studies. we successfully demonstrated the safety and efficacy of RESPILIQ™. Our research and development aim to prolong the survival of the patients with COPD and, above all, improving their quality of life.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Current gold standard therapies for CO2 removal from the human body either focus on increasing the CO2 elimination via the lung by mechanical ventilation or involve extracorporeal systems that pass blood through a gas exchange membrane outside of the human body. RESPILIQ™ is the first medical product developed for capturing CO2 via the intestines, delivering a highly effective therapy in a significant less invasive way.